Erratum: Sorafenib priming may augment salvage chemotherapy in relapsed and refractory FLT3-ITD-positive acute myeloid leukemia (Blood Cancer Journal (2014) 4 (e237) DOI: 10.1038/bcj.2014.59)

KD Cummins; SM Jane; S Ninkovic; A Bazargan; R Filshie; G Sutrave; M Hertzberg; A Scott; S Lane; CK Yannakou; D Ritchie; J D'Rozario; J Black; K Bavishi; A Wei

Journal article

Erratum: Sorafenib priming may augment salvage chemotherapy in relapsed and refractory FLT3-ITD-positive acute myeloid leukemia (Blood Cancer Journal (2014) 4 (e237) DOI: 10.1038/bcj.2014.59)

KD Cummins, SM Jane, S Ninkovic, A Bazargan, R Filshie, G Sutrave, M Hertzberg, A Scott, S Lane, CK Yannakou, D Ritchie, J D'Rozario, J Black, K Bavishi, A Wei

Blood Cancer Journal | Published : 2014

DOI: 10.1038/bcj.2014.68

University of Melbourne Researchers

Ali Bazargan Author Medicine - St Vincent's Hospital

Erratum: Sorafenib priming may augment salvage chemotherapy in relapsed and refractory FLT3-ITD-positive acute myeloid leukemia (Blood Cancer Journal (2014) 4 (e237) DOI: 10.1038/bcj.2014.59)

University of Melbourne Researchers

STUDY AT MELBOURNE

ABOUT US

CONTACT & MAPS

ALUMNI & FRIENDS

RESEARCH

ENGAGEMENT